Boehringer Ingelheim

Greater Good Charities and Boehringer Ingelheim Kick Off Fourth Year of Good Flights Program and Celebrate Successful Transport of More Than 12,800 Shelter Pets to Adoptive Homes Including Nearly 1,300 Asymptomatic Heartworm-Positive Dogs

Retrieved on: 
Monday, April 8, 2024
DSM-IV codes, PLUS, Transport, Disease, Moxidectin, Seizure, Boehringer Ingelheim, Tablet, Diarrhea, Life, House, Dog, Lethargy, Euthanasia, Greater good, Coccidioides immitis, Safety, Terrebonne Parish, Louisiana, Good, Hookworm, Pet, Cat, Atmosphere of Earth, Itch, Animal rescue, Vomiting, Flea, Heart, Boehringer Ingelheim Animal Health, Pharmaceutical industry

To kick off the fourth year of Good Flights, a special transport of more than 45 shelter pets will take place on April 8 from Louisiana to the East Coast.

Key Points: 
  • To kick off the fourth year of Good Flights, a special transport of more than 45 shelter pets will take place on April 8 from Louisiana to the East Coast.
  • Air and ground transports for Good Flights occur approximately five times a month and many have Save a Heart pets on them.
  • “The Good Flights Program and Save a Heart initiative represents a remarkable collaboration between Greater Good Charities and Boehringer Ingelheim,” said Dr. Julie Ryan-Johnson, Senior Associate Director - Shelter Engagement Program, Boehringer Ingelheim.
  • Good Flights covers transport costs, provides mentorship, pharmaceuticals, and furnishes much needed supplies including pet crates, bowls, and leashes.

AAFA's Advocacy for Health Equity Leads to White House Address on Asthma Inhaler Pricing

Retrieved on: 
Wednesday, April 3, 2024
AAFA, Conditional sentence, AstraZeneca, Health equity, Part, GSK, Boehringer Ingelheim, Patient, Asthma, Medicare (United States), Medicaid, Medicare, Inflation, Government

The White House invited AAFA President and CEO, Kenneth Mendez, and Jenna Riemenschneider, AAFA Senior Director of Policy and Advocacy, in recognition of the advocacy group’s work to advance health equity for people with asthma.

Key Points: 
  • The White House invited AAFA President and CEO, Kenneth Mendez, and Jenna Riemenschneider, AAFA Senior Director of Policy and Advocacy, in recognition of the advocacy group’s work to advance health equity for people with asthma.
  • “On behalf of the 27 million people in the United States with asthma, we appreciate the leadership of President Biden and Senator Sanders to bring down costs for asthma treatments.
  • Pricing announcements made in March by some manufacturers of inhalers will mean lower costs and improved access to asthma medicine for many people with asthma starting this June,” stated Mendez.
  • “Lower out-of-pocket costs have the potential to drastically improve asthma health outcomes.

Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, Fulvestrant, NMPA, AstraZeneca, Disease, Progression-free survival, CDX, Boehringer Ingelheim, Patient, Webcast, NGS, Hospital, Breast, Breakthrough, Safety, HR, Depreciation, ID, Precision, Food, Marketing, FDA, Cryptocurrency

Precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine in June 2023.

Key Points: 
  • Precision oncology diagnostics product supports advancement in late-stage breast cancer treatment, with results published in the New England Journal of Medicine in June 2023.
  • Total value of new contracts entered into during 2023 amounted to RMB310 million, representing a 24% increase from 2022.
  • Revenues were RMB121.1 million (US$17.1 million) for the three months ended December 31, 2023, representing a 14.9% decrease from RMB142.2 million for the same period in 2022.
  • Burning Rock will host a conference call to discuss the fourth quarter and full year 2023 financial results at 8:00 a.m. U.S. Eastern Time (8:00 p.m. Hong Kong time) on March 29, 2024.

SPEVIGO® approved for expanded indications in China and the US

Retrieved on: 
Tuesday, March 19, 2024
Arthralgia, Urinary tract infection, Uncertainty, Human, NMPA, Psoriasis, Disease, Multiple organ dysfunction syndrome, Incidence, Risk, GPP, Boehringer Ingelheim, Patient, Ageing, Executive officer, Immunoglobulin G, Anxiety, Doctor of Philosophy, MD, Quality of life, Flare, Injection site reaction, Clinical trial, Skin, Fever, Immune system, Pain, Itch, Food, FDA, Yale University, Fear

In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.

Key Points: 
  • In the trial with 123 patients, no flares were observed after week 4 of SPEVIGO® subcutaneous treatment in the high-dose group (n=30).13,14,15,16 In the Effisayil® 2 trial, SPEVIGO® was associated with an increased incidence (≥9 cases per 100 patient-years) of injection site reaction, urinary tract infection, arthralgia, and pruritus compared to placebo.
  • “Until now, people living with GPP have not had any approved options to treat their disease,” said Bruce Strober, MD, PhD, Clinical Professor, Dermatology, Yale University and Central Connecticut Dermatology.
  • “Experiencing GPP can be mentally and physically devastating, leaving those affected with uncertainty and fear of the next episode.
  • Therefore, expanding the treatment of GPP is a critical step towards addressing patients’ needs.”

Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer

Retrieved on: 
Monday, March 18, 2024
DAS, Retina, University, Moorfields Eye Hospital, Pathology, Oligonucleotide, Ranibizumab, Data analysis, Partnership, Business, Boehringer Ingelheim, DME, Patient, Pharming, Research, Royal College of Ophthalmologists, Cell biology, Diabetic retinopathy, C3, University College London, MBA, Eye, Johnson & Johnson, Janssen, Drug development, John Radcliffe Hospital, AMD, CLS, University of Oxford, Royal college, Geographic atrophy, Stargardt disease, DMI, Pharmaceutical industry

ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.

Key Points: 
  • ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Victor Chong, M.D., MBA was appointed Chief Medical Officer on March 14, 2024.
  • George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer of Clearside, commented, “Victor is a well-known and well-respected retinal clinician and scientist, who is a strategically focused and visionary leader.
  • We are delighted to have him join the Clearside team.
  • “With the upcoming ODYSSEY data and extensive partnership portfolio, this is an exciting time to join Clearside.

American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Against Kidney Disease

Retrieved on: 
Friday, March 15, 2024
American Kidney Fund, Candid (organization), Disease, Caregiver, Vertex Pharmaceuticals, Risk, GSK, Boehringer Ingelheim, GSK plc, Kidney disease, AKF, Therapy, Kidney, Eli Lilly and Company, Platinum, Charity Navigator, Corporation, Pharmaceutical industry

ROCKVILLE, Md., March 15, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is pleased to announce its 2024 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program .

Key Points: 
  • ROCKVILLE, Md., March 15, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) is pleased to announce its 2024 Class of Corporate Members who serve as strategic partners in AKF’s Corporate Membership Program .
  • Corporate Members provide essential support to AKF as it continues its fight against kidney disease on all fronts—from prevention through post-transplant living.
  • “Our Corporate Members—both new and returning—help make the work AKF does for the kidney community possible,” said LaVarne A. Burton, AKF President and CEO.
  • Corporate Members fund AKF’s essential work, including:
    Award-winning, evidence-based kidney health education resources that reach millions of people living with kidney disease, caregivers, living organ donors and health care providers each year
    The Corporate Membership Program is open to institutional partners that support AKF’s mission of fighting kidney disease and helping people live healthier lives.

Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

Retrieved on: 
Tuesday, March 12, 2024
Research, Internal medicine, Overweight, Weill Cornell Medicine, The Obesity Society, Facial muscles, Obesity, Weight loss, SARM, Enobosarm, Education, Flyte, Metabolism, Patient, Weight, Pfizer, Obesity medicine, Davidoff, MD, Weill Cornell Medical Center, Jacobi Medical Center, Eli Lilly and Company, Bangladesh Technical Education Board, MOVE, Boehringer Ingelheim, Directory, Pharmaceutical industry

He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.

Key Points: 
  • He is founder and Chief Scientific Advisor of Intellihealth a cloud-based weight management system which delivers obesity treatment online as flyte.
  • Weight loss through any modality produces muscle loss, and there is an unmet need to minimize that in certain groups of patients in order to produce better quality weight loss.
  • In conjunction with a GLP-1 drug, enobosarm has the potential to deliver better quality weight loss while utilizing lower doses of the GLP-1 drug.
  • We are fortunate that Dr. Aronne and the other senior expert members of our Scientific Advisory Board will help guide the enobosarm development program.”

Pharmaceutical Industry Medical Affairs and Market Access Veteran John Byrd, PhD, MBA to Join AESARA as VP, Management Consulting

Retrieved on: 
Wednesday, April 3, 2024
Health Technology, Health Insurance, Other Health, Marketing, Pharmaceutical, Practice Management, Communications, Managed Care, Mental Health, General Health, Hospitals, Biotechnology, Alternative Medicine, AIDS, Health, GSK, Boehringer Ingelheim, Market access, Novartis, Management consulting, Communication

We are pleased to announce the appointment of John Byrd as VP, Management Consulting at AESARA, a digital-forward Value & Evidence agency that develops innovative and trusted solutions to power transformative market access.

Key Points: 
  • We are pleased to announce the appointment of John Byrd as VP, Management Consulting at AESARA, a digital-forward Value & Evidence agency that develops innovative and trusted solutions to power transformative market access.
  • Ruslan Horblyuk, Chief Strategic Consulting Officer at AESARA, said, "John brings an unmatched breadth and depth of Medical Affairs and Market Access expertise at a time when we are focused on expanding our Management Consulting portfolio and capabilities at AESARA.
  • In his prior roles, John set the vision and strategic direction to ensure effective communication and implementation of value evidence, population health management and quality improvement programs.
  • I look forward to helping the company expand the capabilities within management consulting while continuing to deliver bold, innovative, and transformative solutions to our clients,” said John Byrd.

OSE Immunotherapeutics Reports Full Year 2023 Financial Results and Provides Business Strategy Update

Retrieved on: 
Wednesday, March 27, 2024
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, HCC, AbbVie, GPCR, Ulcerative colitis, Head, Alpha globulin, Survival, Data science, Data analysis, Drug discovery, Partnership, Hook effect, HNSCC, Boehringer Ingelheim, Inflammation, Patient, Research, RNA, Veloxis Pharmaceuticals, Cancer, Lung cancer, Bank statement, AACR, Investment, First, Therapy, ESMO, Collaboration, Hepatocellular carcinoma, RNA therapeutics, FDA, Artificial intelligence, Audit committee, Food, Pharmaceutical industry

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.

Key Points: 
  • OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today reported its consolidated annual financial results for 2023 and provided an update on key proprietary clinical and preclinical achievements, on ongoing collaboration and licensing agreements, as well as on the 2024 Company’s outlook.
  • Anne-Laure Autret-Cornet, Chief Financial Officer of OSE Immunotherapeutics, adds: “Our business-model is mostly based on recurrent and strategic partnerships with pharmaceutical companies.
  • A meeting of the Board of Directors of OSE Immunotherapeutics was held on March 27, 2024.
  • Following the Audit Committee opinion, the Board approved the annual and consolidated financial statements prepared under IFRS on 31 December 2023.

MOMA Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer

Retrieved on: 
Monday, March 11, 2024
Biotechnology, Pharmaceutical, Health, Oncology, MOMA, Georgetown University Law Center, Eli Lilly, Growth, Learning, Science, Partnership, Boehringer Ingelheim, Patient, SVP, Roche, Acquisition, Cancer, IPO, Thought, MBA, Doctor of Philosophy, Investigational New Drug, Johns Hopkins University, Therapy, Heart, Eli Lilly and Company, FDA, Knowledge

MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced that Jullian G. Jones, Ph.D., J.D., MBA, has been appointed as the company’s chief business officer.

Key Points: 
  • MOMA Therapeutics, a biopharmaceutical company discovering and developing a new generation of precision therapeutics via insights derived from the company’s KnowledgeBase platform, today announced that Jullian G. Jones, Ph.D., J.D., MBA, has been appointed as the company’s chief business officer.
  • “We are thrilled to welcome Jullian to MOMA.
  • She has an exceptional track record of thinking and acting strategically and creatively across different business dimensions, while leading with heart and a passion for mentorship,” said Asit Parikh, M.D., Ph.D., chief executive officer of MOMA.
  • “Jullian’s expertise is perfectly aligned with MOMA’s business needs at this stage of our growth and positions us more strongly for success.